CA3233622A1 - Benzimidazole and azabenzimidazole il-17 inhibitor compounds - Google Patents

Benzimidazole and azabenzimidazole il-17 inhibitor compounds Download PDF

Info

Publication number
CA3233622A1
CA3233622A1 CA3233622A CA3233622A CA3233622A1 CA 3233622 A1 CA3233622 A1 CA 3233622A1 CA 3233622 A CA3233622 A CA 3233622A CA 3233622 A CA3233622 A CA 3233622A CA 3233622 A1 CA3233622 A1 CA 3233622A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233622A
Other languages
English (en)
French (fr)
Inventor
Steven D. Goldberg
Douglas C. Behenna
Steven A. LOSKOT
Stefan J. MCCARVER
Timothy B. RHORER
Kristen G. SONG
Alexander E. VALDES
Craig R. Woods
Xiaohua XUE
Brock T. Shireman
Virginia M. Tanis
Deane GORDON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3233622A1 publication Critical patent/CA3233622A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3233622A 2021-09-27 2022-09-26 Benzimidazole and azabenzimidazole il-17 inhibitor compounds Pending CA3233622A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163248561P 2021-09-27 2021-09-27
US63/248,561 2021-09-27
US202163273395P 2021-10-29 2021-10-29
US63/273,395 2021-10-29
PCT/US2022/076999 WO2023049885A1 (en) 2021-09-27 2022-09-26 Benzimidazole and azabenzimidazole il-17 inhibitor compounds

Publications (1)

Publication Number Publication Date
CA3233622A1 true CA3233622A1 (en) 2023-03-30

Family

ID=83995644

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233622A Pending CA3233622A1 (en) 2021-09-27 2022-09-26 Benzimidazole and azabenzimidazole il-17 inhibitor compounds

Country Status (5)

Country Link
US (1) US20250122181A1 (https=)
EP (1) EP4408837A1 (https=)
JP (1) JP2024536868A (https=)
CA (1) CA3233622A1 (https=)
WO (1) WO2023049885A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2024163365A1 (en) * 2023-01-30 2024-08-08 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
CN117567323A (zh) * 2023-10-30 2024-02-20 湖北泰盛化工有限公司 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法
WO2025104230A1 (en) * 2023-11-17 2025-05-22 Sanofi Benzoxazoles as modulators of il-17a

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009273844A1 (en) 2008-07-25 2010-01-28 Gilead Sciences, Inc. Antiviral compounds
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
CN113999234B (zh) * 2020-07-28 2023-03-07 成都先导药物开发股份有限公司 一种免疫调节剂

Also Published As

Publication number Publication date
JP2024536868A (ja) 2024-10-08
WO2023049885A1 (en) 2023-03-30
US20250122181A1 (en) 2025-04-17
EP4408837A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
CA3233622A1 (en) Benzimidazole and azabenzimidazole il-17 inhibitor compounds
CA2660520C (en) Hepatitis c virus inhibitors
TWI886474B (zh) Tlr7/8拮抗劑及其用途
CA2715839C (en) Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
RU2684324C1 (ru) Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4
CN104540385B (zh) 嘧啶基酪氨酸激酶抑制剂
CA3181676A1 (en) Imidazopyridazines as modulators of il-17
KR20200113216A (ko) Ｒｈｏ 관련 단백질 키나아제의 조절인자로서의 헤테로사이클릴아미노 치환 트리아졸
TW201121955A (en) Hepatitis C virus inhibitors
CA3233625A1 (en) Imidazopyridazine il-17 inhibitor compounds
TW201940485A (zh) 作為激酶抑制劑之胺基吡咯并三
CA3233408A1 (en) Imidazopyridazine il-17 inhibitor compounds
US12252480B2 (en) Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1H-1,2,3-triazole-4-carboxamide
US20220402950A1 (en) Substituted benzimidazoles as pad4 inhibitors
CA3181793A1 (en) Imidazopyrimidines as modulators of il-17
KR20220072857A (ko) 질병 치료용 수용체 상호작용 단백질 키나아제 i 의 억제제
US8648074B2 (en) Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
CA3233410A1 (en) Benzimidazoles as modulators of il-17
US20130085142A1 (en) SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
CN118139859A (zh) 苯并咪唑和氮杂苯并咪唑il-17抑制剂化合物
WO2025202931A1 (en) Imidazopyridazine il-17 inhibitor compounds
JP2016503007A (ja) 疼痛治療におけるカルシウムチャネル遮断薬として有用なジアゼピン誘導体
WO2025202922A1 (en) Imidazopyridazine il-17 inhibitor compounds
US20250353848A1 (en) Heterocyclic pad4 inhibitors
CA3032133C (en) Chemokine receptor modulators and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805